有机化学人才网 | 最新人才 | 最新职位 | 技术交易 | 药物合成 |
   
全站搜索: |
  您当前位置:网站首页 >> 药物合成路线图解
 

药物详细合成路线

Name Atorvastatin calcium;YM-548;CI-981;Prevencor;Tahor;Lipibec;Torvast;Sortis;Lipitor
Chemical Name (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxyheptanoic acid calcium salt (2:1)
CAS 134523-03-8
Related CAS 134523-00-5 (free acid), 110862-48-1 (free acid (R*, R*)-isomer)
Formula C66H68CaF2N4O10
Structure
Formula Weight 1155.37546
Stage 上市-1997
Company Jouveinal (Originator), Pfizer (Originator), Almirall Prodesfarma (Licensee), Syncro (Licensee), Yamanouchi (Licensee), Stanford University (Codevelopment)
Activity/Mechanism Alzheimers Dementia, Treatment of , CARDIOVASCULAR DRUGS, Cognition Disorders, Treatment of, Immunologic Neuromuscular Disorders, Treatment of, Lipoprotein Disorders, Treatment of , METABOLIC DRUGS, Multiple Sclerosis, Agents for, NEUROLOGIC DRUGS, Treatment of Disorders of the Coronary Arteries and Atherosclerosis, HMG-CoA Reductase Inhibitors, TNFSF6 Expression Inhibitors
Syn. Route 11
Route 1
1) the condensation of 2-(1,3-dixolan-2-yl)ethylamine (i) with ethyl 2-bromo-2-(4-fluorophenyl)acetate (ii) by means of triethylamine in acetonitrile gives ethyl 2-[2-(1,3-dioxolan-2-yl)ethylamino]-2-(4-fluorophenyl)acetate (iii), which is acylated with isobutyryl chloride (iv) and triethylamine in dichloromethane yielding the corresponding amide (v). saponification of the ester (v) with naoh in methanol/water affords the free acid (vi), which is cyclized with n,3-diphenylpropynamide (vii) [obtained in the reaction of 3-phenylpropynoic acid (viii) with aniline (ix) by means of dicyclohexylcarbodiimide (dcc)] by heating at 90 c in acetic anhydride giving 1-[2-(1,3-dioxolan-2-yl)ethyl]-5-(4-fluorophenyl)-2-isopropyl-n,4-diphenylpyrrole-3-carboxamide (x). the hydrolysis of the dioxolane group of (x) with hcl yields the corresponding aldehyde (xi), which is condensed with methyl acetoacetate (xii) by means of nah in thf affording 7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(n-phenylcarbamoyl)pyrrol-1-yl]-5-hydroxy-3-oxoheptanoic acid methyl ester (xiii). the reduction of the carbonyl group of (xiii) with tributylborane and nabh4 in thf gives the (3r*,5r*)-dihydroxy ester (xiv), which is saponified with naoh in water yielding the corresponding free acid (xv). the lactonization of (xv) by heating in refluxing toluene affords the (r*,r*)-lactone (xvi), which is submitted to optical resolution by reaction with (r)-1-phenylethylamine (xvii) followed by fractional crystallization thus obtaining the amide (xvii) as the pure (r,r,r)-enantiomer. the hydrolysis of the amide (xviii) with naoh, followed by heating in refluxing toluene gives the (r,r)-lactone (xix), which is finally treated first with naoh in methanol/water, and then with cacl2 or calcium acetate.
List of intermediates No.
2,3,6,7-tetrahydrofuro[2,3-f][1]benzofuran (xvii)
7-ethynyl-4,4-dimethyl-3,4-dihydro-1(2h)-naphthalenone (xii)
1-ethyl-6,7,8-trifluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (ix)
4-(4-phenylbutoxy)benzaldehyde (iv)
mesitylboronic acid (i)
2,4,6-trimethyl[1,1-biphenyl]-2-amine (ii)
ethyl (e)-3-(2-mesitylanilino)-2-butenoate (iii)
4-chloro-8-mesityl-2-methylquinoline (v)
n-(cyclopropylmethyl)-1-propanamine (vi)
4-(2,4-dimethoxyphenyl)-3-methyl-1h-pyrazol-5-amine (vii)
3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-ol (viii)
n-(2-methoxyethyl)-1-propanamine (x)
indole-2-carboxylic acid methyl ester; 1h-indole-2-carboxylic acid methyl ester (xi)
3-cyclopentyl-1-propanol (xiii)
3-cyclopentylpropyl methanesulfonate (xiv)
1-(3-iodopropyl)cyclopentane (xv)
1-phenyl-1,4-dihydro-5h-1,2,3,4-tetraazol-5-one (xix)
1-(3-cyclopentylpropyl)-4-(4-nitrophenyl)-1,4-dihydro-5h-1,2,3,4-tetraazol-5-one (xvi)
Reference 1:
    graul, a.; castaner, j.; atorvastatin calcium. drugs fut 1997, 22, 9, 956.
Reference 2:
    roth, b.d.; blankley, c.j.; chucholowski, a.w.; ferguson, e.; hoefle, m.l.; ortwine, d.f.; newton, r.s.; sekerke, c.s.; sliskovic, d.r.; stratton, c.d.; wilson, m.w.; inhibitors of cholesterol biosynthesis. 3. tetrahydro-4-hydroxy-6-[2-(1h-pyrrol-1-yl)ethyl]-2h-pyran-2-one inhibitors of hmg-coa reductase. 2. effects of introducing substituents at positions three and four of the pyrrole nucleus. j med chem 1991, 34, 1, 357-66.
Reference 3:
    roth, b.d. (pfizer inc.); trans-6-[2-(3- or 4-carboxamido-substd. pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis. ep 0247633; us 4681893 .
Reference 4:
    roth, b.d. (pfizer inc.); (r-(r*r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl-3 -phenyl-4-[(phenylamino)-carbonyl]-1h-pyrrole-1-heptanoic acid, its lactone form and salts thereo. ep 0409281; jp 1991058967; us 5273995 .
Reference 5:
    mills, n.; muhammad, n.a.; weiss, j.; nesbitt, r.u. (pfizer inc.); stable oral ci-981 formulation and process for preparing same. ep 0680320; jp 1996505640; us 5686104; wo 9416693 .

Route 2
2) the condensation of the previously described aldehyde (xi) with (s)-(+)-2-acetoxy-1,1,2-triphenylethanol (xx) by means of lithium diisopropylamide (lda) in thf gives 5-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(n-phenylcarbamoyl)pyrrol-1-yl]-3(r)-hydroxypentanoic acid 2-hydroxy-1(s),2,2-triphenylethyl ester (xxi), which is trans-esterified with sodium methoxide in methanol/thf yielding the expected methyl ester (xxii). the condensation of (xxii) with tert-butyl acetate (xxiii) by means of lda in thf affords (r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(n-phenylcarbamoyl) pyrrol-1-yl]-5-hydroxy-3-oxoheptanoic acid tert-butyl ester (xxiv), which is reduced with triethylborane and nabh4 in thf, hydrolyzed with naoh, lactonized by heating in refluxing toluene and finally submitted to fractional crystallization in order to separate the two diastereomers of the obtained lactone, (r,r) and (r,s). the (r,r)-diastereomer (xix), already obtained, is finally treated with naoh and then with cacl2.
List of intermediates No.
2-chromanone (xx)
indole-2-carboxylic acid methyl ester; 1h-indole-2-carboxylic acid methyl ester (xi)
1-phenyl-1,4-dihydro-5h-1,2,3,4-tetraazol-5-one (xix)
4-[4-(3-cyclopentylpropyl)-5-oxo-4,5-dihydro-1h-1,2,3,4-tetraazol-1-yl]benzenesulfonyl chloride (xxi)
tert-butyl 4-[([4-[4-(3-cyclopentylpropyl)-5-oxo-4,5-dihydro-1h-1,2,3,4-tetraazol-1-yl]phenyl]sulfonyl)amino]phenethyl[(2r)-2-hydroxy-2-(3-pyridinyl)ethyl]carbamate (xxii)
3-cyclopentylpropionic acid (xxiii)
1-(3-azidopropyl)cyclopentane (xxiv)
Reference 1:
    roth, b.d.; blankley, c.j.; chucholowski, a.w.; ferguson, e.; hoefle, m.l.; ortwine, d.f.; newton, r.s.; sekerke, c.s.; sliskovic, d.r.; stratton, c.d.; wilson, m.w.; inhibitors of cholesterol biosynthesis. 3. tetrahydro-4-hydroxy-6-[2-(1h-pyrrol-1-yl)ethyl]-2h-pyran-2-one inhibitors of hmg-coa reductase. 2. effects of introducing substituents at positions three and four of the pyrrole nucleus. j med chem 1991, 34, 1, 357-66.
Reference 2:
    graul, a.; castaner, j.; atorvastatin calcium. drugs fut 1997, 22, 9, 956.
Reference 3:
    roth, b.d. (pfizer inc.); (r-(r*r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl-3 -phenyl-4-[(phenylamino)-carbonyl]-1h-pyrrole-1-heptanoic acid, its lactone form and salts thereo. ep 0409281; jp 1991058967; us 5273995 .
Reference 4:
    mills, n.; muhammad, n.a.; weiss, j.; nesbitt, r.u. (pfizer inc.); stable oral ci-981 formulation and process for preparing same. ep 0680320; jp 1996505640; us 5686104; wo 9416693 .

Route 3
3) the condensation of 4-cyano-3(r)-hydroxybutyric acid ethyl ester (xxxv) with n,n-diphenylacetamide (r1 = r2 = ph in xxvi) by means of lda in thf gives 6-cyano-5(r)-hydroxy-3-oxo-n,n-diphenylhexanamide (xxvii), which is reduced with diethylmethoxyborane and nabh4 in thf yielding 6-cyano-3(r),5(r)-dihydroxy-n,n-diphenylhexanamide (xxviii). the protection of the two oh groups of (xxviii) with acetone dimethylketal (xxix) and methanesulfonic acid affords the 1,3-dioxane (xxx), which by reduction of its cn group by hydrogenation with h2 over rani in methanol/liquid ammonia gives intermediate (4r,6r)-2-[6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl]-n,n-diphenylacetamide (xxxi). the cyclization of (xxxi) with 4-(4-fluorophenyl)-2-isobutyryl-4-oxo-n-phenylbutyramide (xxxii) (its synthesis is in section 6, scheme 18007204a) in refluxing toluene yields the protected dihydroxyheptanamide (xxxiii), which is deprotected with hcl in methanol to afford (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(n-phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-n,n-diphenylheptanamide (xxxiv). finally, this compound is hydrolyzed with naoh and treated with calcium acetate in water.4) the preceding reaction pathway can be repeated using other substituents for r1 and r2 in acetamide (xxvi) such as r1 = r2 = ch2ph; r1 = r2 = et; r1 = bu, r2 = me; r1 = t-bu, r2 = ch2ph; r1,r2 = -(ch2)5-.
List of intermediates No.
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[2-(methylsulfanyl)ethyl]amino]-2-[(3,3,3-trifluoropropyl)sulfanyl]-9h-purin-9-yl]tetrahydro-3,4-furandiol (xxix)
4-aminobenzenesulfonic acid (xxv)
4-isocyanatobenzenesulfonyl chloride (xxvia)
6-bromohexanoic acid (xxvib)
phenyl(3-pyridinyl)methanone (xxvic)
(z)-7-phenyl-7-(3-pyridinyl)-6-heptenoic acid (xxvid)
(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-ol (xxvie)
3,5-dichlorobenzoyl chloride (xxviia)
1-methyl-2-pyrrolidinimine (xxviib)
n-(1-methyl-2-pyrrolidinylidene)-n-phenylthiourea (xxviic)
1-methyl-2-[[(methylsulfanyl)(phenylimino)methyl]imino]pyrrolidine (xxviid)
1,4-dichloro-5,8-dihydroxyanthra-9,10-quinone (xxviie)
1,4-bis(benzyloxy)-5,8-dichloroanthra-9,10-quinone (xxviiia)
2-[(2-hydrazinoethyl)amino]-1-ethanol (xxviiib)
7,10-bis(benzyloxy)-5-chloro-2-[2-[(2-hydroxyethyl)amino]ethyl]dibenzo[cd,g]indazol-6(2h)-one (xxviiic)
n-(2-aminoethyl)-n-methylamine (xxviiid)
1-[(3-chloropropyl)sulfanyl]benzene (xxviiie)
1,3-dimethyl-7-(2-oxiranylmethyl)-3,7-dihydro-1h-purine-2,6-dione (xxxa)
diethyl 2-methyl-3-oxosuccinate (xxxb)
ethyl 2-[(e)-2-phenylhydrazono]propanoate (xxxc)
Reference 1:
    graul, a.; castaner, j.; atorvastatin calcium. drugs fut 1997, 22, 9, 956.
Reference 2:
    butler, d.e.; le, t.v.; nanninga, t.n. (pfizer inc.); process for trans-6-[2-(substd.-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis. us 5298627 .

Route 4
5) the hydrolysis of methyl (et or bu) 3(r)-(tert-butyldimethylsilyloxy)-4-cyanobutyrate (xxv) with naoh gives the corresponding free acid (xxxvi), which is condensed with malonic acid mono-tert-butyl ester magnesium salt (xxxvii) by means of carbonyldiimidazole (cdi) yielding tert-butyl 5(r)-(tert-butyldimethylsilyloxy)-6-cyano-3-oxohexanoate (xxxviii). the desilylation of (xxxviii) with tetrabutylammonium fluoride in acetic acid affords the expected hydroxylated ketoester (xxxix), which is reduced with diethylmethoxyborane and nabh4 in methanol giving tert-butyl 6-cyano-3(r),5(r)-dihydroxyhexanoate (xl). the protection of the two oh groups of (xl) with acetone dimethylketal (xxix) and methanesulfonic acid affords the 1,3-dioxane (xli) (6), which by reduction of its cn group by hydrogenation with h2 over pd/c gives intermediate (4r,6r)-2-[6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid tert-butyl ester (xlii).6) the (4r,6r)-2-[6-(cyanomethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid tert-butyl ester (xli) can also be obtained by reaction of (4r,6r)-2-[6-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid tert-butyl ester (xlviii) with tosyl chloride to give the corresponding tosylate (xvix), which is then treated with nacn.7) the tert-butyl 6-cyano-5(r)-hydroxy-3-oxohexanoate (xxxix) can also be obtained by condensation of methyl 4-cyano-3(r)-hydroxybutyrate (l) with tert-butyl acetate (xxiii) by means of lda in thf.
List of intermediates No.
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[2-(methylsulfanyl)ethyl]amino]-2-[(3,3,3-trifluoropropyl)sulfanyl]-9h-purin-9-yl]tetrahydro-3,4-furandiol (xxix)
4-((e)-3-[[3-(heptyloxy)-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-7-quinolinyl]amino]-3-oxo-1-propenyl)-2,6-dimethoxyphenyl acetate (xxiii)
7-(benzyloxy)-2-(3,4-dimethoxyphenyl)-5-methoxy-4h-chromen-4-one (xxxv)
2-(3,4-dimethoxyphenyl)-7-hydroxy-5-methoxy-4h-chromen-4-one (xxxvi)
tert-butyl 2-[[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4h-chromen-7-yl]oxy]acetate (xxxvii)
(2s)oxiranylmethyl 3-pyridinyl ether (xxxviii)
(2s)-1-[(4-nitrophenethyl)amino]-3-(3-pyridinyloxy)-2-propanol (xxxix)
tert-butyl (2s)-2-hydroxy-3-(3-pyridinyloxy)propyl(4-nitrophenethyl)carbamate (xl)
tert-butyl 4-aminophenethyl[(2s)-2-hydroxy-3-(3-pyridinyloxy)propyl]carbamate (xli)
4-iodobenzenesulfonyl chloride (xlii)
tert-butyl (2s)-2-hydroxy-3-(3-pyridinyloxy)propyl(4-[[(4-iodophenyl)sulfonyl]amino]phenethyl)carbamate (xlviii)
n-(5-hydroxy-2-pyridinyl)acetamide (xlix)
n-[5-[(2s)oxiranylmethoxy]-2-pyridinyl]acetamide (l)
Reference 1:
    graul, a.; castaner, j.; atorvastatin calcium. drugs fut 1997, 22, 9, 956.
Reference 2:
    roth, b.d.; baumann, k.l.; butler, d.e.; deering, c.f.; mennen, k.e.; millar, a.; nanninga, t.n.; palmer, c.w.; the convergent synthesis of ci-981, an optically active, highly potent, tissue selective inhibitor of hmg-coa reductase. tetrahedron lett 1992, 33, 17, 2283-4.
Reference 3:
    brower, p.l.; butler, d.e.; deering, c.f.; le, t.v.; millar, a.; nanninga, t.n.; roth, b.d.; the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for the preparation of ci-981, a highly potent, tissue selective inhibitor of hmg-coa reductase. tetrahedron lett 1992, 33, 17, 2279-82.

Route 5
8) the synthesis of the 4-(4-fluorophenyl)-2-isobutyryl-4-oxo-n-phenylbutyramide (xxxii) is carried out as follows: the condensation of 4-methyl-3-oxo-n-phenylpentanamide (xliv) with benzaldehyde (xlv) gives 2-benzylidene-4-methyl-3-oxo-n-phenylpentanamide (xlvi), which is then condensed with 4-fluorobenzaldehyde (xlvii) by means of triethylamine in hot ethanol.9) the cyclization of (xxxii) with intermediate (xlii) (preceding synthesis) in refluxing toluene yields the protected dehydroxyheptanoate (xliii), which is deprotected with hcl in methanol and finally hydrolyzed with naoh and treated with calcium acetate in water.
List of intermediates No.
methyl 3-[5-(2-chlorophenyl)-2-oxo-2,3-dihydro-1h-thieno[2,3-e][1,4]diazepin-7-yl]propanoate (xlv)
methyl (1r,2s,3r)-3-acetyl-4-oxo-2-(3-phenylpropyl)cyclopentanecarboxylate (xlvii)
5,5-dimethyl-8-oxo-5,6,7,8-tetrahydronaphthalen-2-yldiazonium tetrafluoroborate (xxxii)
4-iodobenzenesulfonyl chloride (xlii)
n-[5-([(2s)-2-hydroxy-3-[(4-nitrophenethyl)amino]propyl]oxy)-2-pyridinyl]acetamide (xliv)
tert-butyl (2s)-3-[[6-(acetamido)-3-pyridinyl]oxy]-2-hydroxypropyl(4-aminophenethyl)carbamate (xlvi)
(e)-3-(4-hydroxyphenyl)-2-propenenitrile (xliii)
Reference 1:
    graul, a.; castaner, j.; atorvastatin calcium. drugs fut 1997, 22, 9, 956.
Reference 2:
    mckenzie, a.t. (pfizer inc.); form iii crystalline (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methyl-ethyl) -3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin). jp 1999509229; wo 9703958 .
Reference 3:
    lin, m.; schweiss, d. (pfizer inc.); novel process for the production of amorphous [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1). jp 1999510486; wo 9703960 .
Reference 4:
    briggs, c.a.; jennings, r.a.; wade, r.a.; harasawa, k.; ichikawa, s.; minohara, k.; nakagawa, s. (pfizer inc.); crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl) -3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin). jp 1999509230; wo 9703959 .

Route 6
the 6-cyanohexanoic ester (vii), intermediate in the synthesis of 180072 (see intermediate (xli) in scheme no. 18007204a) has been obtained as follows: the reaction of 1,6-heptadien-4-ol (i) with buli, co2, and i2 in thf gives the cyclic carbonate (ii), which is treated with ts-oh in acetone to yield the acetonide (iii). the reaction of the iodine atom of (iii) with kcn in hot dmso affords the nitrile (iv), which is oxidized at the terminal double bond with oso4 and naio4, or o3 and me2s, to provide the carbaldehyde (v). the oxidation of (v) with cro3/h2so4 in acetone gives the carboxylic acid (vi), which is finally esterified with tert-butanol by means of dcc and dmap in dichloromethane, yielding the target ester intermediate (vii).
List of intermediates No.
tert-butyl 4-aminophenethyl[(2s)-2-hydroxy-3-(3-pyridinyloxy)propyl]carbamate (vii)
Reference 1:
    radl, s.; et al.; an improved synthesis of 1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for atorvastatin synthesis. tetrahedron lett 2002, 43, 11, 2087.

Route 7
the synthesis of ring labeled [14c]-atorvastatin has been described: the grignard reaction of phenylmagnesium chloride (i) with [14c]-labeled co2 (ii) in thf/ethyl ether gives the benzoic acid (iii), which is reduced with lialh4 in ethyl ether to the benzyl alcohol (iv). the oxidation of (iv) with pyridinium dichromate affords the benzaldehyde (v), which is condensed with the isobutyrylacetamide (vi) by means of beta-alanine in acetic acid yielding a mixture of the cis- and trans-benzylidene derivatives (vii). the condensation of (vii) with 4-fluorobenzaldehyde (viii) by means of triethylamine and a thiazolium bromide catalyst affords the 1,4-dione (ix), which is cyclized with the chiral amino ester (x) in hot heptane/toluene/thf providing the protected pyrroloheptanoic ester (xi). the deprotection of (xi) in acidic medium, followed by the hydrolysis of the ester group with naoh affords the sodium salt (xii), which is finally treated with calcium acetate in thf/water.
List of intermediates No.
4-methoxybenzyl (7r)-7-([2-([[(1s)-2-(benzhydryloxy)-1-methyl-2-oxoethyl]oxy]imino)-2-[2-(tritylamino)-1,3-thiazol-4-yl]acetyl]amino)-8-oxo-3-[([1,3]thiazolo[4,5-c]pyridin-2-ylsulfanyl)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (iii)
methyl 3-[5-(2-chlorophenyl)-2-oxo-2,3-dihydro-1h-thieno[2,3-e][1,4]diazepin-7-yl]propanoate (v)
methyl (1r,2s,3r)-3-acetyl-4-oxo-2-(3-phenylpropyl)cyclopentanecarboxylate (viii)
5,5-dimethyl-8-oxo-5,6,7,8-tetrahydronaphthalen-2-yldiazonium tetrafluoroborate (ix)
4-iodobenzenesulfonyl chloride (x)
n-[5-([(2s)-2-hydroxy-3-[(4-nitrophenethyl)amino]propyl]oxy)-2-pyridinyl]acetamide (vi)
tert-butyl (2s)-3-[[6-(acetamido)-3-pyridinyl]oxy]-2-hydroxypropyl(4-aminophenethyl)carbamate (vii)
(e)-3-(4-hydroxyphenyl)-2-propenenitrile (xi)
4,5-dimethyl-1,3-dioxol-2-one (iv)
4-benzyl 1-(tert-butyl) (2r,3r)-2-(cyclopentylmethyl)-3-[(methylamino)methyl]butanedioate (i)
(2r,3r)-4-(benzyloxy)-2-(cyclopentylmethyl)-3-[(methylamino)methyl]-4-oxobutyric acid (xii)
ethyl 2-[2-(benzyloxy)-5-cyanophenoxy]-6-[3-(1-methyl-4,5-dihydro-1h-imidazol-2-yl)phenoxy]isonicotinate (v)
methyl (2r,3r)-2-(3-cyanobenzyl)-3-{[4-(4-pyridinyl)benzoyl]amino}butanoate (iii)
4-[4-({[(1r,2r)-2-(3-cyanobenzyl)-3-methoxy-1-methyl-3-oxopropyl]amino}carbonyl)phenyl]-1-pyridiniumolate (iv)
4-(4-{[((1r,2r)-2-{3-[imino(methoxy)methyl]benzyl}-3-methoxy-1-methyl-3-oxopropyl)amino]carbonyl}phenyl)-1-pyridiniumolate (vii)
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(1-piperidinyl)-1h-pyrazole-3-carboxamide (ix)
5-(4-chlorophenyl)-1-(2,4-dichloro-6-iodophenyl)-4-methyl-n-(1-piperidinyl)-1h-pyrazole-3-carboxamide (xi)
5-(4-chlorophenyl)-1-(2,4-dichloro-3-iodophenyl)-4-methyl-n-(1-piperidinyl)-1h-pyrazole-3-carboxamide (xii)
Reference 1:
    woo, p.w.k.; et al.; atorvastatin, an hmg-coa reductase inhibitor and efficient lipid-regulating agent. part i. synthesis of ring-labeled [c-14] atorvastatin. j label compd radiopharm 1999, 42, 2, 121.

Route 8
the synthesis of atorvastatin [14c]-labeled on the side chain has been described: the reaction of [14c]-labeled sodium acetate (i) with phthaloyl chloride (ii) in refluxing xylene gives the acyl chloride (iii), which is treated with 1,2,2-triphenyl-1(s),2-ethanediol (iv) in dichloromethane yielding the expected monoacetate (v). the condensation of (v) with the pyrrolepropionaldehyde (vi) by means of lithium diisopropylamide (lda) in thf affords the chiral beta-hydroxyester (vii), which is transesterified with sodium methoxide in methanol providing the corresponding methyl ester (viii). the condensation of (viii) with tert-butyl acetate (ix) by means of lda in thf gives the beta-oxo-delta-hydroxyester (x), which is regioselectively reduced to the dihydroxyester (xi) by means of bet3, nabh4 and h2o2 in thf. the hydrolysis of (xi) with naoh in thf/water, followed by acidification yields the free acid (xii), which is heated in refluxing toluene in a dean-stark trap to provide lactone (xiii). the reaction of (xiii) with naoh in thf/methanol gives the corresponding sodium salt (xiv), which is finally treated with cacl2 in the same solvent.
List of intermediates No.
2-chromanone (v)
indole-2-carboxylic acid methyl ester; 1h-indole-2-carboxylic acid methyl ester (vi)
1-(3-iodopropyl)cyclopentane (xii)
1-phenyl-1,4-dihydro-5h-1,2,3,4-tetraazol-5-one (xiii)
4-[4-(3-cyclopentylpropyl)-5-oxo-4,5-dihydro-1h-1,2,3,4-tetraazol-1-yl]benzenesulfonyl chloride (vii)
tert-butyl 4-[([4-[4-(3-cyclopentylpropyl)-5-oxo-4,5-dihydro-1h-1,2,3,4-tetraazol-1-yl]phenyl]sulfonyl)amino]phenethyl[(2r)-2-hydroxy-2-(3-pyridinyl)ethyl]carbamate (viii)
3-cyclopentylpropionic acid (ix)
1-(3-azidopropyl)cyclopentane (x)
5-iodo-2-[(2-methoxyethoxy)methoxy]benzaldehyde; 5-iodo-2-[(2-methoxyethoxy)methoxy]benzaldehyde (iii)
1-(methylsulfonyl)-2-imidazolidinone (ii)
(2r,3r)-4-(benzyloxy)-2-(cyclopentylmethyl)-3-[(methylamino)methyl]-4-oxobutyric acid (xiv)
benzyl (2r,3r)-3-(cyclopentylmethyl)-2-[[methyl(methylsulfonyl)amino]methyl]-4-oxo-4-(1-piperidinyl)butanoate (i)
(2r,3r)-3-(cyclopentylmethyl)-2-[[methyl(methylsulfonyl)amino]methyl]-4-oxo-4-(1-piperidinyl)butyric acid (iv)
n-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-1h-imidazole-1-carboxamide (xi)
methyl 2-methyl-2-phenylpropanoate; methyl alpha,alpha-dimethylbenzeneacetate (i)
4-[4-(2-methoxy-1,1-dimethyl-2-oxoethyl)phenyl]-4-oxobutanoic acid (iii)
methyl 2-[4-(4-{4-[hydroxy(diphenyl)methyl]-1-piperidinyl}-4-oxobutanoyl)phenyl]-2-methylpropanoate (v)
methyl 2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]-1-piperidinyl}butyl)phenyl]-2-methylpropanoate (vii)
10-hydroxy-10,11-dihydro-5h-dibenzo[b,f]azepine-5-carboxamide (viii)
1,3-dibromo-2-methylbenzene; 2,6-dibromotoluene (x)
Reference 1:
    woo, p.w.k.; lee, h.t.; atorvastatin, an hmg-coa reductase inhibitor and effective lipid-regulating agent. part ii. synthesis of side-chain-labeled [c-14] atorvastatin. j label compd radiopharm 1999, 42, 2, 129.

Route 9
the synthesis of atorvastatin has been described: the condensation of benzaldehyde (i) with the isobutyrylacetamide (ii) by means of beta-alanine in acetic acid yields a mixture of cis- and trans-benzylidene derivatives (iii). the condensation of (iii) with 4-fluorobenzaldehyde (iv) by means of triethylamine and a thiazolium bromide catalyst affords the 1,4-dione (v), which is cyclized with the chiral amino ester (vi) in hot heptane/toluene/thf to provide the protected pyrroloheptanoic ester (vii). the deprotection of (vii) in acidic medium, followed by the hydrolysis of the ester group with naoh affords the sodium salt (viii), which is finally treated with calcium acetate in thf/water.
List of intermediates No.
methyl 3-[5-(2-chlorophenyl)-2-oxo-2,3-dihydro-1h-thieno[2,3-e][1,4]diazepin-7-yl]propanoate (i)
methyl (1r,2s,3r)-3-acetyl-4-oxo-2-(3-phenylpropyl)cyclopentanecarboxylate (iv)
5,5-dimethyl-8-oxo-5,6,7,8-tetrahydronaphthalen-2-yldiazonium tetrafluoroborate (v)
4-iodobenzenesulfonyl chloride (vi)
n-[5-([(2s)-2-hydroxy-3-[(4-nitrophenethyl)amino]propyl]oxy)-2-pyridinyl]acetamide (ii)
tert-butyl (2s)-3-[[6-(acetamido)-3-pyridinyl]oxy]-2-hydroxypropyl(4-aminophenethyl)carbamate (iii)
(e)-3-(4-hydroxyphenyl)-2-propenenitrile (vii)
(2r,3r)-4-(benzyloxy)-2-(cyclopentylmethyl)-3-[(methylamino)methyl]-4-oxobutyric acid (viii)
Reference 1:
    woo, p.w.k.; et al.; atorvastatin, an hmg-coa reductase inhibitor and effective lipid regulating agent. part iii. synthesis of [h-2(5)]-, [c-13(8)], and [c-13(7)],n-15]atorvastatin and their application in metabolic and pharmacokinetic studies. j label compd radiopharm 1999, 42, 2, 135.

Route 10
the synthesis of atorvastatin has been described: the condensation of benzaldehyde (i) with the isobutyrylacetamide (ii) by means of beta-alanine in acetic acid yields a mixture of cis- and trans-benzylidene derivatives (iii). the condensation of (iii) with 4-fluorobenzaldehyde (iv) by means of triethylamine and a thiazolium bromide catalyst affords the 1,4-dione (v), which is cyclized with the chiral amino ester (vi) in hot heptane/toluene/thf to provide the protected pyrroloheptanoic ester (vii). the deprotection of (vii) in acidic medium, followed by the hydrolysis of the ester group with naoh affords the sodium salt (viii), which is finally treated with calcium acetate in thf/water.
List of intermediates No.
methyl 3-[5-(2-chlorophenyl)-2-oxo-2,3-dihydro-1h-thieno[2,3-e][1,4]diazepin-7-yl]propanoate (i)
methyl (1r,2s,3r)-3-acetyl-4-oxo-2-(3-phenylpropyl)cyclopentanecarboxylate (iv)
5,5-dimethyl-8-oxo-5,6,7,8-tetrahydronaphthalen-2-yldiazonium tetrafluoroborate (v)
4-iodobenzenesulfonyl chloride (vi)
n-[5-([(2s)-2-hydroxy-3-[(4-nitrophenethyl)amino]propyl]oxy)-2-pyridinyl]acetamide (ii)
tert-butyl (2s)-3-[[6-(acetamido)-3-pyridinyl]oxy]-2-hydroxypropyl(4-aminophenethyl)carbamate (iii)
(e)-3-(4-hydroxyphenyl)-2-propenenitrile (vii)
(2r,3r)-4-(benzyloxy)-2-(cyclopentylmethyl)-3-[(methylamino)methyl]-4-oxobutyric acid (viii)
Reference 1:
    woo, p.w.k.; et al.; atorvastatin, an hmg-coa reductase inhibitor and effective lipid regulating agent. part iii. synthesis of [h-2(5)]-, [c-13(8)], and [c-13(7)],n-15]atorvastatin and their application in metabolic and pharmacokinetic studies. j label compd radiopharm 1999, 42, 2, 135.

Route 11
the synthesis of atorvastatin has been described: the condensation of benzaldehyde (i) with the isobutyrylacetamide (ii) by means of beta-alanine in acetic acid yields a mixture of cis- and trans-benzylidene derivatives (iii). the condensation of (iii) with 4-fluorobenzaldehyde (iv) by means of triethylamine and a thiazolium bromide catalyst affords the 1,4-dione (v), which is cyclized with the chiral amino ester (vi) in hot heptane/toluene/thf to provide the protected pyrroloheptanoic ester (vii). the deprotection of (vii) in acidic medium, followed by the hydrolysis of the ester group with naoh affords the sodium salt (viii), which is finally treated with calcium acetate in thf/water.
List of intermediates No.
methyl 3-[5-(2-chlorophenyl)-2-oxo-2,3-dihydro-1h-thieno[2,3-e][1,4]diazepin-7-yl]propanoate (i)
methyl (1r,2s,3r)-3-acetyl-4-oxo-2-(3-phenylpropyl)cyclopentanecarboxylate (iv)
5,5-dimethyl-8-oxo-5,6,7,8-tetrahydronaphthalen-2-yldiazonium tetrafluoroborate (v)
4-iodobenzenesulfonyl chloride (vi)
n-[5-([(2s)-2-hydroxy-3-[(4-nitrophenethyl)amino]propyl]oxy)-2-pyridinyl]acetamide (ii)
tert-butyl (2s)-3-[[6-(acetamido)-3-pyridinyl]oxy]-2-hydroxypropyl(4-aminophenethyl)carbamate (iii)
(e)-3-(4-hydroxyphenyl)-2-propenenitrile (vii)
(2r,3r)-4-(benzyloxy)-2-(cyclopentylmethyl)-3-[(methylamino)methyl]-4-oxobutyric acid (viii)
Reference 1:
    woo, p.w.k.; et al.; atorvastatin, an hmg-coa reductase inhibitor and effective lipid regulating agent. part iii. synthesis of [h-2(5)]-, [c-13(8)], and [c-13(7)],n-15]atorvastatin and their application in metabolic and pharmacokinetic studies. j label compd radiopharm 1999, 42, 2, 135.

来源:药化网

作者:药化小编

摘要:本文合成路线介绍的是药物中文名阿托伐他汀钙;英文名Atorvastatin calcium;YM-548;CI-981;Prevencor;Tahor;Lipibec;Torvast;Sortis;Lipitor;CAS[134523-03-8]

 
推荐VIP企业
无锡景耀生物科技有限公司
杭州卢普生物科技有限公司
宁波赛伦化工有限公司
苏州昊赛生物科技有限公司
北京嘉盛扬医药科技有限公司
上海泽涵生物医药科技有限公司
河北固安三利化工公司
郑州凯普瑞生物技术有限公司
上海药谷药业有限公司
兰州康寓信生物科技有限公司
湖北朗昕生化药业有限公司
武汉福鑫化工有限公司
嘉兴市英南化工有限公司
苏州迪飞医药科技有限公司
北京富安凯科技有限公司
上海盛中医药化工有限公司
连云港天和化学有限公司
南京晨瑞医药科技有限公司
南京苏如化工有限公司
常州瑞盛化工有限公司
热门文章
华东地区BDO市场延续弱势整理
华南地区BDO市场难逃弱势
华东地区丁二烯市场弱势盘整
陕西地区醋酸价格
山东地区环己酮市场行情
浙江地区二氯甲烷价格暂稳
河南地区醋酸价格
河南地区醋酸价格
华北地区BDO市场淡稳整理
江西地区二氯甲烷价格上调
江苏地区醋酸价格
河北地区醋酸价格
华北苯酐市场行情
河北地区醋酸价格
山东地区三氯甲烷价格
华北地区丁二烯市场观望为主
山东地区辛醇市场行情
山东地区醋酸价格
华北地区BDO市场疲态不改
山东地区二氯甲烷市场价格上调
 友情链接
有机化学人才网  
首页 | 广告服务 | 建站服务 | 关于我们 | 联系我们 | 版权声明